Skip to main content

Table 2 Univariate and multivariate analyses for breast cancer-specific survival

From: Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society

Variables Univariate analysis Multivariate analysis
HRs (95% CI) P value HRs (95% CI) P value
A. Hormone receptor-positive     
Pathological stage   .001   .001
 Stage I 1.00   1.00  
 Stage II 2.81 (1.82–4.34)   1.81 (0.87–3.76)  
 Stage III 14.34 (9.50–21.67)   5.99 (2.34–15.34)  
Tumor size: > 5 vs. ≤ 5 cm 6.82 (4.81–9.68) .001 1.59 (0.83–3.03) .159
LNR: Above vs. Below mean 4.10 (3.07–5.47) .001 1.24 (0.64–2.38) .527
Histological grade: G3 vs. G1/2 4.20 (3.14–5.60) .001 3.41 (2.04–5.69) .001
Lymphatic invasion: Yes vs. No 3.28 (2.44–4.41) .001 1.65 (0.94–2.89) .079
Vascular invasion: Yes vs. No 2.70 (1.94–3.75) .001 0.79 (0.42–1.49) .471
Ki-67: < 14 vs. ≥ 14% 0.54 (0.34–0.84) .006 0.95 (0.57–1.56) .825
HER2: Low vs. IHC 0 0.61 (0.44–0.85) .003 0.72 (0.44–1.17) .186
B. Hormone receptor-negative     
Pathological stage   .001   .001
 Stage I 1.00   1.00  
 Stage II 2.80 (1.89–4.14)   2.03 (1.35–3.05)  
 Stage III 12.95 (8.77–19.13)   3.95 (2.34–6.63)  
Tumor size: > 5 vs. ≤ 5 cm 5.38 (3.97–7.29) .001 1.94 (1.38–2.74) .001
LNR: Above vs. Below mean 4.89 (3.83–6.26) .001 1.92 (1.37–2.67) .001
Histological grade: G3 vs. G1/2 1.29 (0.95–1.73) .102   
Lymphatic invasion: Yes vs. No 4.27 (3.29–5.53) .001 1.74 (1.23–2.46) .006
Vascular invasion: Yes vs. No 3.88 (2.96–5.09) .001 1.38 (0.99–0.19) .132
Ki-67: < 14 vs. ≥ 14% 0.90 (0.54–1.49) .691   
HER2: Low vs. IHC 0 0.69 (0.50–0.95) .023 0.68 (0.49–0.93) .019